155 related articles for article (PubMed ID: 36087622)
1. TMEM244 Gene Expression as a Potential Blood Diagnostic Marker Distinguishing Sézary Syndrome from Mycosis Fungoides and Benign Erythroderma.
Rassek K; Iżykowska K; Żurawek M; Nowicka K; Joks M; Olek-Hrab K; Olszewska B; Sokołowska-Wojdyło M; Biernat W; Nowicki RJ; Przybylski GK
J Invest Dermatol; 2023 Feb; 143(2):344-347.e3. PubMed ID: 36087622
[No Abstract] [Full Text] [Related]
2. Histopathologic studies in Sézary syndrome and erythrodermic mycosis fungoides: a comparison with benign forms of erythroderma.
Sentis HJ; Willemze R; Scheffer E
J Am Acad Dermatol; 1986 Dec; 15(6):1217-26. PubMed ID: 2948972
[TBL] [Abstract][Full Text] [Related]
3. A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.
Luherne C; Menguy S; Ferte T; Beylot-Barry M; Seneschal J; Milpied B; Vial JP; Gros A; Amintas S; Vergier B; Pham-Ledard A
Acta Derm Venereol; 2022 Sep; 102():adv00773. PubMed ID: 35758515
[TBL] [Abstract][Full Text] [Related]
4. Mycosis fungoides? Sezary syndrome.
Roenigk HH; Taylor JG
Arch Dermatol; 1970 Feb; 101(2):244-6. PubMed ID: 4244178
[No Abstract] [Full Text] [Related]
5. Gene rearrangement studies in lymphoproliferative disorders of skin.
Weiss LM; Wood GS; Nickoloff BJ; Sklar J
Adv Dermatol; 1988; 3():141-60. PubMed ID: 3152817
[No Abstract] [Full Text] [Related]
6. Sézary cell count in exfoliative dermatitis.
Duangurai K; Piamphongsant T; Himmungnan T
Int J Dermatol; 1988 May; 27(4):248-52. PubMed ID: 2968960
[TBL] [Abstract][Full Text] [Related]
7. Circulating Sézary cells. A new preparatory method for their identification and enumeration.
Fletcher V; Zackheim HS; Beckstead JH
Arch Pathol Lab Med; 1984 Dec; 108(12):954-8. PubMed ID: 6239604
[TBL] [Abstract][Full Text] [Related]
8. Genotyping of cutaneous T-cell lymphomas and pseudolymphomas.
Bignon YJ; Souteyrand P
Curr Probl Dermatol; 1990; 19():114-23. PubMed ID: 2404672
[No Abstract] [Full Text] [Related]
9. The MicroRNA Expression Profile Differs Between Erythrodermic Mycosis Fungoides and Sézary Syndrome.
Rittig AH; Lindahl LM; Johansen C; Celis P; Ødum N; Iversen L; Litman T
Acta Derm Venereol; 2019 Nov; 99(12):1148-1153. PubMed ID: 31453630
[TBL] [Abstract][Full Text] [Related]
10. Hypomethylation of the promoter region drives ectopic expression of TMEM244 in Sézary cells.
Iżykowska K; Rassek K; Żurawek M; Nowicka K; Paczkowska J; Ziółkowska-Suchanek I; Podralska M; Dzikiewicz-Krawczyk A; Joks M; Olek-Hrab K; Giefing M; Przybylski GK
J Cell Mol Med; 2020 Sep; 24(18):10970-10977. PubMed ID: 32794659
[TBL] [Abstract][Full Text] [Related]
11. Mycosis fungoides and Sézary syndrome.
Espinet B; Salgado R
Methods Mol Biol; 2013; 973():175-88. PubMed ID: 23412790
[TBL] [Abstract][Full Text] [Related]
12. Interleukin 4 and interferon-gamma expression of the dermal infiltrate in patients with erythroderma and mycosis fungoides. An immuno-histochemical study.
Sigurdsson V; Toonstra J; Bihari IC; Bruijnzeel-Koomen CA; van Vloten WA; Thepen T
J Cutan Pathol; 2000 Oct; 27(9):429-35. PubMed ID: 11028812
[TBL] [Abstract][Full Text] [Related]
13. [The Sézary syndrome].
Ferreira F; Correia TM; Callabro L; Andrade J
Acta Med Port; 1998 Dec; 11(12):1135-9. PubMed ID: 10192992
[TBL] [Abstract][Full Text] [Related]
14. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous T cell lymphomas: mycosis fungoides, Sézary syndrome and lymphomatoid papulosis--part II.
Safai B
Clin Bull; 1977; 7(4):140-5. PubMed ID: 147147
[No Abstract] [Full Text] [Related]
16. [Clinical characteristics of mycosis fungoides and Sézary syndrome].
Krc L; Dobesová J; Bucek M; Dusek J; Macák J; Galuszková D; Jurysek O
Vnitr Lek; 1997 May; 43(5):285-9. PubMed ID: 9601850
[TBL] [Abstract][Full Text] [Related]
17. T-plastin (PLS3) gene expression differentiates Sézary syndrome from mycosis fungoides and inflammatory skin diseases and can serve as a biomarker to monitor disease progression.
Tang N; Gibson H; Germeroth T; Porcu P; Lim HW; Wong HK
Br J Dermatol; 2010 Feb; 162(2):463-6. PubMed ID: 19995369
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
Jfri A; Smith JS; Larocca C
J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
[No Abstract] [Full Text] [Related]
19. Mycosis fungoides and the Sézary syndrome.
Gisselbrecht C; Dubertret L
Nouv Rev Fr Hematol (1978); 1993 Feb; 35(1):73-5. PubMed ID: 8511044
[No Abstract] [Full Text] [Related]
20. Management of mycosis fungoides. Part 1. Diagnosis, staging, and prognosis.
Smith BD; Wilson LD
Oncology (Williston Park); 2003 Sep; 17(9):1281-8. PubMed ID: 14569854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
